Nanobiotix is trading 6.4% up in pre-market at $27.40; no clear company-specific catalyst for the October 5 move was identified in available coverage.
- The October 2 report of first Phase 1 esophageal cancer study data is prior news, and reporting does not link it to this pre-market rise.
- The broader market is little changed to slightly lower; volume and other activity details were unavailable.